Alemtuzumab is a highly effective therapy for relapsing-remitting MS (RRMS) with secondary autoimmunity as a main adverse event. Here, we present a case of microscopic polyangiitis (MPA) in a patient with RRMS secondary to alemtuzumab therapy.

Case report {#s1}
===========

A 47-year-old Caucasian woman was diagnosed with RRMS at the age of 35 years and treated with glatiramer acetate, teriflunomide, and natalizumab. After positive anti-JCV antibody status and stopping natalizumab, 2 disabling relapses occurred. She was switched to alemtuzumab and received 2 cycles without side effects and a stable disease course. Seventeen months after the last alemtuzumab infusion, she developed an erythematous, purpura-like exanthema of the lower legs and the general condition deteriorated. Laboratory testing showed thrombocytosis, mild anemia, leukocytosis with relative lymphopenia, and mildly elevated CRP levels. Skin biopsy of the erythema together with immunohistochemistry revealed infiltration with neutrophils, lymphocytes, and eosinophils around the small blood vessels in the dermis, multifocal red blood cells, and fragmented neutrophilic nuclei, consistent with mild nongranulomatous leukocytoclastic vasculitis ([figure](#F1){ref-type="fig"}, A-C). No vessel necrosis was observed. Further laboratory studies indicated elevated perinuclear antineutrophil cytoplasmic antibody (pANCA) levels, negative anti-GBM antibodies, and normal antistreptolysin O titer, eosinophils, rheumatoid factor, and thyroid function. CD4^+^ T cells were relatively reduced, whereas levels of CD19+/CD20+ B cells were elevated. There was no clinical, laboratory, or imaging evidence of a pulmonary-renal syndrome. Approximately 5 years after diagnosis of RRMS, pANCA values were still normal. MPA was diagnosed based on the presence of small-vessel vasculitis and myeloperoxidase (MPO)-ANCA without proteinase-3-ANCA. Methylprednisolone was administered IV followed by a gradual oral taper. Skin and laboratory changes relieved quickly, and pANCA levels decreased. After recovery of lymphocytes, B-cell depletion with rituximab may serve as a treatment option for both RRMS and MPA.^[@R1]^
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Discussion {#s2}
==========

MPA is a necrotizing small-vessel vasculitis with common focal necrotizing, pauci-immune glomerulonephritis, pulmonary capillaritis, and purpura.^[@R1],[@R2]^ In our patient, diagnosis of MPA was confirmed by purpura-like exanthema in the context of leukocytoclastic vasculitis and the characteristic detection of MPO-ANCA in the absence of thrombocytopenia. The pathogenesis of MPA likely comprises an interplay between neutrophils, lymphocytes, endothelium, cytokine-mediated changes, the alternative pathway of the complement system, and MPO-ANCA.^[@R2]^ For maintenance immunosuppression, rituximab, methotrexate, mycophenolate mofetil, or azathioprine is recommended.^[@R1]^

In our case, an association between alemtuzumab treatment and MPA may be assumed, although a causal relationship cannot be confirmed. Alemtuzumab, a humanized monoclonal antibody against the surface glycoprotein CD52 temporarily depletes B and T cells and induces prolonged T-cell lymphopenia.^[@R3]^ It is associated with secondary B cell--mediated autoimmunity mostly affecting the thyroid, less frequently immune thrombocytopenia or glomerular nephropathies.^[@R3]^ Uncommon complications such as antiglomerular basement membrane disease^[@R4]^ or leukocytoclastic vasculitis^[@R5]^ were also reported. These antibody-mediated autoimmune diseases may stem from an altered immune repertoire with early and predominant recovery of B cells. The occurrence of MPA in our patient fits well with the time frame in which B-cell reconstitution occurs following alemtuzumab.^[@R3]^ The overshooting B-cell repopulation including potentially autoreactive B cells emerging in the relative absence of T-cell regulation may explain the resulting secondary autoimmunity in our case.^[@R3]^ Since B-lymphocytes are essential in the pathogenesis of MPA^[@R2]^ and RRMS, B-cell depletion would be a promising strategy to control B-cell hyperproliferation.

MPA should be considered in the differential diagnosis of purpura-like efflorescence after alemtuzumab therapy. Early identification and immediate treatment are vital to resolve symptoms, prevent pulmonary-renal damage, and minimize mortality.
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